

Date-August 09,2024

To
BSE Ltd.
P. J. Towers
Dalal Street,
Mumbai - 400 001.

BSE Scrip Code: 524444

Subject: Outcome of the Board Meeting held on August 09,2024

Dear Sir/Mam

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Evexia Lifecare Limited ('the Company') at its meeting held today, i.e., August 09, 2024, has approved the following:

1. The Unaudited Standalone and Consolidated Financial Results with the Limited Review Report for the quarter ended June 30, 2024.
2. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company on have approved the proposal for re-appointment of Ms. Payal Gajjar (DIN: 08745777) as an Independent Director of the Company for a second term of 5 (five) consecutive years commencing from March 24, 2025 up to March 23, 2030 (both days inclusive), subject to approval of the members in the ensuing AGM.

Pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India Limited with ref no. NSE/CML/2018/24, dated June 20, 2018, the above mentioned proposed director are not debarred from holding the office of director pursuant to any SEBI order or any other authority.

The disclosure as required to be given pursuant to SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is enclosed as **Annexure A**.

3. Convene the 33rd AGM of the Members of the Company on Tuesday, September 24, 2024. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM").
4. The Register of members and Share Transfer Books of the Company will remain closed from Wednesday, September 18, 2024 to Saturday, September 24, 2024 (both days inclusive) for the purpose of the above referred 33rd Annual General Meeting.

The meeting of the Board of Directors commenced at 07:30 p.m. and concluded at 8:30 p.m.

This is for your information and records.

Thanking You,
Yours faithfully,

For Evexia Lifecare Limited

JAYESHKUMAR
RAICHANDBHAI
THAKKAR

Digitally signed by
JAYESHKUMAR RAICHANDBHAI
THAKKAR
Date: 2024.08.09 20:32:35 +05'30'

JAYESHBHAI R. THAKKAR
MANAGING DIRECTOR
DIN: 01631093

The disclosure as required to be given pursuant to SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Details of events that need to be provided	Information of such event(s)
1	Reason for change viz. re-appointment, resignation,	Ms. Payal Gajjar (DIN: 08745777) current tenure as an Independent Director of the Company expires on March 23, 2025. Based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company on August 09, 2024 have approved the reappointment of Ms. Payal Gajjar (DIN: 08745777) for a second term of 5 (five) consecutive years commencing from March 24, 2025 up to March 23, 2030, subject to approval of the members.
2	Date of reappointment & term of reappointment	Re-appointment for a term of 5 years with effect from March 24, 2025.
3	Brief Profile (in case of appointment);	Ms. Payal Gajjar is experienced in planning & designing various architectural projects and interior design schemes, she has shown keen interest in managing and mentoring multiple project teams and client handling. On Delivery side owning multiple delivery projects across Vadodara region from technology perspective and helping teams on Architecture work, Cross Platform Integrations, Cloud Migrations and Go-Live stages. Handling 50+ Member team from Project Management & Technical front both.
4.	Disclosure of relationships between directors. Ms. Payal Gajjar	Ms. Payal Gajjar is not related to any Director or Key Managerial Personnel of the Company.
5.	Name of other listed entities in which he also holds the directorship	NIL
6.	Name of Committee(s) of listed entity(s) in which he is chairman/Member	NIL
7.	Shareholding, if any in the Company.	NIL



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors
Evexia Lifecare Limited.
(Formerly known as Kavita Industries Limited)

Disclaimer of Conclusion.

1. We were engaged to review the accompanying Statement of unaudited Standalone financial results of Evexia Lifecare Limited for the quarter ended 30th June 2024, ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. It is the responsibility of the Company's Management and Board of Directors to Preparation of this Statement from the individual final accounts in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The statement has been approved by the Parent Company's Board of Directors.
3. Our responsibility is to conduct a review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit conclusion.





We are also responsible for performing procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Due to the matters described in the paragraph below, we were not able to obtain sufficient evidence to provide a basis for conclusion on the Statement and hence we do not express a conclusion on the Statement.

Basis of Disclaimer of Conclusion.

- a. We draw attention to the Note No 4 to the Financial Results, which indicates that Loans receivables of Rs. 1470.96/- lakhs, which have significant increase in credit risk, in respect of which the Company has not made any assessment for expected credit loss, in accordance with the requirements of 'Ind AS 109: Financial instruments', as the management considers such balances as good and recoverable in future. In the absence of such assessment for expected credit loss by the Management and any other evidence to corroborate the Management's assessment, we are unable to comment on the recoverability of these balances and the consequent impact, if any, on the provision thereon and the loss to be reported in the financial results.
- b. We draw attention to the Note No 5 to the Financial Results, which indicates that Trade Receivables amounting to Rs. 4164.51/- lakhs, which have significant increase in credit risk, in respect of which the Company has not made any assessment for expected credit loss, in accordance with the requirements of 'Ind AS 109: Financial instruments', as the management considers such balances as good and recoverable in future. In the absence of such assessment for expected credit loss by the Management and any other evidence to corroborate the Management's assessment, we are unable to comment on the recoverability of these balances and the consequent impact, if any, on the provision thereon and the loss reported in the financial results.
- c. We draw attention to the Note No to 6 the Financial Results, which indicates that company has made investments in unquoted equity shares of the companies amounting to Rs. 87.39/- Lakhs for which company is unable to determine fair valuation of its investments.





- d. We draw attention to the Note No 7 to the Financial Results, which indicates that company has subsidiary "Kavit Edible Oil Limited" which has suspended its manufacturing operations since March, 2019. Company has exposure of Rs. 123.23/- Lakhs in form of Equity and unsecured loan and company's subsidiary has negative net worth as of June 30th, 2024. These conditions raised substantial doubt about its ability as going concern.
- e. We draw attention to the Note No 08 to the Financial Results, regarding the Company had not restated its financial liability of Foreign Currency Convertible Bonds as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates ". had this restatement was done as per Ind AS 21, Profit after tax for the year and consequently profit for the quarter ended June 30th 2024 would have been lower by Rs. 677.18/-Lakhs.
- f. We draw attention to the Note No 09 to the Financial Results, regarding the Company had not restated its financial liability on the conversion of the Foreign Currency Convertible Bonds and the foreign exchange difference between the recognition of the liability and de-recognition of liability is being reduced from the remaining liability of the FCCB. Had this amount is being recognised as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates" the profit for the quarter ended would have been lower by Rs.124.45 /- Lakhs.

Emphasis of Matter

- a. We draw attention to the Note No 4 to the financial results in respect of the Interest free loans granted by the Company to associates concern and others of RS.3238.73/- Lakhs, the terms and conditions including repayment thereof have not been stipulated by the Company.
- b. We draw attention to the Note No 10 to the Financial Results, regarding the Company has adjusted the amortised discount cost and issue expenses on the issue of the Foreign Currency Convertible Bond against the balance laying in the Security Premium Account.

Our Opinion is not modified in respect of these matters





Other Matter

During the period under review, Pursuant to receipt of Conversion notice from holder of the FCCBs, the company had allotted 7,13,96,581 Equity shares at Rs.2.34 /- (Issue price) on 01/04/2024 and 26,21,58,577 Equity Shares at 2.39/-(Issue price) on 17/06/2024 in lieu of conversion of 20 and 75 FCCBs Bonds accordingly out of total 974 FCCBs.

For

Tejas K. Soni and Company.

Chartered Accountants

Firm Registration No: 135093W

Proprietor

Membership No: 150418

UDIN: 24150418BKAJIN 4954.



Date: 9th August, 2024.

Place: Vadodara

EVEXIA LIFECARE LIMITED(FORMERLY KNOWN AS KAVIT INDUSTRIES LIMITED)
Regd. Office : Tundav Anjesar Road, Vil: Tundav, Tal: Savli, Dist: Vadodara - 391775.
CIN NO. L23100GJ1990PLC014692

Phone No: 0265 - 2361100

Email ID: info@evexialifecare.com
(Rs. In Lakhs)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2024

Sr No	Particulars	Quarter Ended			Year Ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	(a) Revenue From Operations	2,041.87	2,364.71	1,401.88	5,489.56
	(b) Other Income	0.23	86.47	-	86.56
	Total Revenue	2,042.10	2,451.18	1,401.88	5,576.12
2	Expenses				
	(a) Cost of materials consumed	10.50	99.73	28.69	192.70
	(b) Purchases of Traded Goods	1,944.52	2,039.99	1,180.75	4,810.68
	(c) Changes in inventories of finished goods, WIP	(0.25)	5.39	50.50	(1.46)
	(d) Employee Benefit Expenses	18.26	28.75	22.73	90.44
	(e) Finance Cost	0.01	48.70	0.14	49.20
	(f) Depreciation and amortisation expense	10.12	15.42	9.68	41.63
	(g) Other expenses	23.23	88.16	99.29	241.43
	Total expenses	2,006.39	2,326.14	1,391.78	5,424.62
3	Profit Before Tax	35.70	125.04	10.09	151.50
4	Tax expense				
	1) Current Tax	9.28	33.90	2.62	33.90
	2) Deferred Tax	-	4.92	-	4.92
	3) Income Tax of Earlier Year	-	(2.58)	-	(2.58)
	Total Tax Expenses	9.28	36.24	2.62	36.24
5	Profit / (Loss) for the period	26.42	88.80	7.47	115.26
6	Other Comprehensive Income/(Loss)				
	(i) Items that will not be reclassified to profit or loss				
	- Remeasurement of Defined benefit plans	-	(2.39)	-	(2.39)
	- Equity instruments through other comprehensive income	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss				
	- Remeasurement of Defined benefit plans	-	0.62	-	0.62
	- Equity instruments through other comprehensive income	-	-	-	-
	Total Other Comprehensive Income	-	(1.77)	-	(1.77)
7	Total Comprehensive income for the period	26.42	90.57	7.47	117.03
	Paid up Equity Share Capital (Face Value of Rs 10/- each)	10,415.68	7,080.13	6,644.33	7,080.13
	Earnings per equity share (in Rs)				
	(a) Basic	0.03	0.014	0.001	0.017
	(b) Diluted	0.03	0.014	0.001	0.017

NOTES :

- The above standalone financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The above standalone financial results have been reviewed and recommended by Audit Committee and have been approved and taken on record by Board of Directors at its meeting on 09th August, 2024.
- The limited review as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of Company
- The Company has granted loans, the terms and conditions including repayment thereof have not been stipulated by the Company, to the Companies and associates concerns of Rs. 3238.73/- lakhs. out of them loans receivables of Rs.1470.96/- lakhs, which have significant increase in credit risk, in respect of which the Company has not made any assessment for expected credit loss, in accordance with the requirements of 'Ind AS 109: Financial Instruments', as the management considers such balances as good and recoverable in future.
- The Company has Trade Receivable amounting to Rs. 4164.51/- lakhs, the same are pertains to the outstanding for more than two to three years. The Company has not either created an ECL provision or impaired the balances of these Trade Receivables in accordance with the requirements of 'Ind AS 109: Financial Instruments', as the management considers such balances as good and recoverable in future.
- In the absence of sufficient information, the company is unable to determine the fair valuation of its investment in the unquoted equity shares of the Companies amounting to Rs. 87.39/- Lakhs as at 30th June, 2024. and consequently adjustments, if any, to the carrying value of investments in unquoted equity shares as at 31st March, 2024 have not been recognized.
- The company has subsidiary "Kavit Edible Oil Limited" which has suspended its manufacturing operations since March, 2019. Company has exposure of Rs. 123.23/- Lakhs in form of Equity and unsecured loan and company's subsidiary has negative net worth as of June 30th, 2024.
- The Company had not restated its financial liability of Foreign Currency Convertible Bonds as per Ind AS 21 " The Effects of Changes in Foreign Exchange Rates ". Had this restatement was done as per Ind AS 21, Profit after tax for the year and consequently Retained Earnings as at March 31st, 2024, would have been lower by Rs.1171.82 /- Lakhs, and for the quarter ended June 30th 2024 would have been lower by Rs. 677.18/-Lakhs.
- The Company had not restated its financial liability on the conversion of the Foreign Currency Convertible Bonds and the foreign exchange difference between the recognition of the liability and de-recognition of liability is being reduced from the remaining liability of the FCCB. Had this amount is being recognised as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates" the profit for the quarter ended would have been lower by Rs.124.45 /- Lakhs.
- The Company has adjusted Rs. 5450.69/- Lakhs amortised discount cost and issue expenses on the issue of the Foreign Currency Convertible Bond against the balance laying in the Security Premium Account.
- Pursuant to receipt of Conversion notice from holder of the FCCBs, the company had allotted 7,13,96,581 Equity shares at Rs.2.34 /- (Issue price) on 01/04/2024 and 26,21,58,577 Equity Sahres at 2.39/-(Issue price) on 17/06/2024 in lieu of conversion of 20 and 75 FCCBs Bonds accordingly, out of total 974 FCCBs.

For Evexia lifecare Limited


Managing Director
DIN: 01631093



Date: 09th August, 2024
Place: Vadodara



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of
Evexia Lifecare Limited
(Formerly known as Kavit Industries Limited)

Disclaimer of Conclusion.

1. We were engaged to review the accompanying Statement of unaudited consolidated financial results of Evexia Lifecare Limited ('the Parent Company') and its subsidiaries (the Parent and its subsidiaries together referred to as 'the Group'), and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the quarter ended June 2024, ('the Statement'), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. It is the responsibility of the Parent Company's Management and Board of Directors to compile this Statement from the individual final accounts prepared by the management of the subsidiaries in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The statement has been approved by the Parent Company's Board of Directors.
3. Our responsibility is to conduct a review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit conclusion.

We are also responsible for performing procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.





Due to the matters described in the paragraph below, we were not able to obtain sufficient evidence to provide a basis for conclusion on the Statement and hence we do not express a conclusion on the Statement.

The Statement includes the results of the entities as per the attached Annexure I.

Basis of Disclaimer of Conclusion.

- a. We draw attention to the Note No 4 to the Financial Results, which indicates that Loans receivables of Rs. 1470.96/- lakhs, which have significant increase in credit risk, in respect of which the Company has not made any assessment for expected credit loss, in accordance with the requirements of 'Ind AS 109: Financial instruments', as the management considers such balances as good and recoverable in future. In the absence of such assessment for expected credit loss by the Management and any other evidence to corroborate the Management's assessment, we are unable to comment on the recoverability of these balances and the consequent impact, if any, on the provision thereon and the loss to be reported in the financial results.
- b. We draw attention to the Note No 5 to the Financial Results, which indicates that Trade Receivables amounting to Rs. 4164.51/- lakhs, which have significant increase in credit risk, in respect of which the Company has not made any assessment for expected credit loss, in accordance with the requirements of 'Ind AS 109: Financial instruments', as the management considers such balances as good and recoverable in future. In the absence of such assessment for expected credit loss by the Management and any other evidence to corroborate the Management's assessment, we are unable to comment on the recoverability of these balances and the consequent impact, if any, on the provision thereon and the loss reported in the financial results.
- c. We draw attention to the Note No to 6 the Financial Results, which indicates that company has made investments in unquoted equity shares of the companies amounting to Rs. 87.39/- Lakhs for which company is unable to determine fair valuation of its investments.
- d. We draw attention to the Note No 7 to the Financial Results, which indicates that company has subsidiary "Kavit Edible Oil Limited" which has suspended its manufacturing operations since March, 2019. Company has exposure of Rs. 123.23/- Lakhs in form of Equity and unsecured loan and company's subsidiary has negative net worth as of June 30th, 2024. These conditions raised substantial doubt about its ability as going concern.





- e. We draw attention to the Note No 08 to the Financial Results, regarding the Company had not restated its financial liability of Foreign Currency Convertible Bonds as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates". Had this restatement was done as per Ind AS 21, Profit after tax for the year and consequently profit for the quarter ended June 30th 2024 would have been lower by Rs. 677.18/-Lakhs.
- f. We draw attention to the Note No 09 to the Financial Results, regarding the Company had not restated its financial liability on the conversion of the Foreign Currency Convertible Bonds and the foreign exchange difference between the recognition of the liability and de-recognition of liability is being reduced from the remaining liability of the FCCB. Had this amount is being recognised as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates" the profit for the quarter ended would have been lower by Rs.124.45 /- Lakhs.

Emphasis of Matter

- a. We draw attention to the Note No 4 to the financial results in respect of the Interest free loans granted by the Company to associates concern and others of RS.3238.73/- Lakhs, the terms and conditions including repayment thereof have not been stipulated by the Company.
- b. We draw attention to the Note No 10 to the Financial Results, regarding the Company has adjusted the amortised discount cost and issue expenses on the issue of the Foreign Currency Convertible Bond against the balance laying in the Security Premium Account.

Our Opinion is not modified in respect of these matters

Other Matter

During the period under review, Pursuant to receipt of Conversion notice from holder of the FCCBs, the company had allotted 7,13,96,581 Equity shares at Rs.2.34 /- (Issue price) on 01/04/2024 and 26,21,58,577 Equity Shares at 2.39/-(Issue price) on 17/06/2024 in lieu of conversion of 20 and 75 FCCBs Bonds accordingly out of total 974 FCCBs.

The accompanying unaudited consolidated financial results includes unaudited interim financial information of Three (3) subsidiaries (including its wholly owned step-down subsidiary) and One (1) associate, which have not been reviewed by their auditors, whose interim financial information reflect total revenues of Rs. 80.92/- Lakhs, total net Loss before tax is Rs. 3.12/- Lakhs for the quarter ended June 2024, as considered in the





unaudited consolidated financial results and have been furnished by the Holding Company's Management

Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on such unaudited/ unreviewed interim financial information. According to the information and explanations given to us by the management, such interim financial information is not material to the Group. Our conclusion is not modified in respect of this matter with respect to our reliance on the interim financial information certified by the Board of Directors.

For
Tejas K. Soni and Company.
Chartered Accountants
Firm Registration No: 135093W



Proprietor
Membership No: 150418
UDIN: 24150418BKAJJ02729.



Date: 9th August, 2024.
Place: Vadodara



Annexure

[To the Auditor's Report on the Consolidated Financial Results of Evexia Lifecare Limited for the quarter ended June 30th, 2024]

Sr No	Name of the Entity	Relationship
1	Kavit Edible Oil Limited	Subsidiary
2	Kavit Trading Private Limited	Subsidiary
4	Evexia Lifecare Africa Limited	Subsidiary
5	Evexia Pan Africa Limited	Step Down Subsidiary
6	Heemsol Energy System Private Limited	Associates



STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2024

Sr No	Particulars	Quarter Ended			Year Ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income				
	(a) Revenue From Operations	2,122.79	2,471.64	1,401.84	5,628.90
	(b) Other Income	13.26	86.47	20.28	86.56
	Total Revenue	2,136.05	2,558.11	1,422.12	5,715.46
2	Expenses				
	(a) Cost of materials consumed	10.50	99.73	28.69	192.70
	(b) Purchases of Traded Goods	2,035.52	2,077.13	1,180.75	4,847.82
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3.01)	31.24	50.50	24.39
	(d) Employee Benefit Expenses	18.26	32.72	23.11	94.41
	(e) Finance Cost	0.38	48.65	0.16	49.21
	(f) Depreciation and amortisation expense	10.12	15.42	9.68	41.63
	(g) Other expenses	31.69	(74.49)	99.47	272.40
	Total Expenses	2,103.47	2,230.39	1,392.36	5,522.56
3	Profit / (Loss) before tax (1-2)	32.58	327.72	29.76	192.90
4	Tax Expense				
	1) Current Tax	8.47	52.87	7.74	52.87
	2) Income Tax of Earlier Year	-	4.92	-	4.92
	3) Deferred Tax	-	(2.58)	-	(2.58)
	Total Tax Expenses	8.47	55.21	7.74	55.21
5	Profit / (Loss) for the Period (3-4)	24.11	272.50	22.02	137.69
6	Other Comprehensive Income / (Loss)				
	(i) Items that will not be reclassified to profit or loss				
	- Remeasurement of Defined benefit plans	-	(2.39)	-	(2.39)
	- Equity instruments through other comprehensive income	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	- Remeasurement of Defined benefit plans	-	0.62	-	0.62
	- Equity instruments through other comprehensive income	-	-	-	-
	Total Other Comprehensive Income	-	(1.77)	-	(1.77)
7	Total Comprehensive Income for the period (5+6)	24.11	274.27	22.02	139.46
8	Paid up Equity Share Capital (Face Value of Rs.10/-each)	10415.68	6,644.33	6,644.33	7,080.13
9	Earnings per Equity Share (EPS) (nominal value of Rs.10/-each) (not annualized) (in Rs)				
	(a) Basic	0.02	0.04	0.03	0.02
	(b) Diluted	0.02	0.04	0.03	0.02

NOTES :

- The above standalone financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The above consolidated financial results have been reviewed and recommended by Audit Committee and have been approved and taken on record by Board of Directors at its meeting on 10th August, 2023.
- The limited review as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of Company
- The Company has granted loans, the terms and conditions including repayment thereof have not be stipulated by the Company, to the Companies and associates concerns of Rs. 3238.73/- lakhs. out of them loans receivables of Rs.1470.96/- lakhs, which have significant increase in credit risk, in respect of which the Company has not made any assessment for expected credit loss, in accordance with the requirements of 'Ind AS 109: Financial Instruments', as the management considers such balances as good and recoverable in future.
- The Company has Trade Receivable amounting to Rs. 4164.51/- lakhs, the same are pertains to the outstanding for more than two to three years. The Company has not either created an ECL provision or impaired the balances of these Trade Receivables in accordance with the requirements of 'Ind AS 109: Financial Instruments', as the management considers such balances as good and recoverable in future.
- In the absence of sufficient information, the company is unable to determine the fair valuation of its investment in the unquoted equity shares of the Companies amounting to Rs. 87.39/- Lakhs as at 30th June, 2024, and consequently adjustments, if any, to the carrying value of investments in unquoted equity shares as at 31st March, 2024 have not been recognized.
- The company has subsidiary "Kavit Edible Oil Limited" which has suspended its manufacturing operations since March, 2019. Company has exposure of Rs. 123.23/- Lakhs in form of Equity and unsecured loan and company's subsidiary has negative net worth as of June 30th, 2024.
- The Company had not restated its financial liability of Foreign Currency Convertible Bonds as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates". Had this restatement was done as per Ind AS 21, Profit after tax for the year and consequently Retained Earnings as at March 31st, 2024, would have been lower by Rs.1171.82 /- Lakhs, and for the quarter ended June 30th 2024 would have been lower by Rs. 677.18/-Lakhs.
- The Company had not restated its financial liability on the conversion of the Foreign Currency Convertible Bonds and the foreign exchange difference between the recognition of the liability and de-recognition of liability is being reduced from the remaining liability of the FCCB. Had this amount is being recognised as per Ind AS 21 "The Effects of Changes in Foreign Exchange Rates" the profit for the quarter ended would have been lower by Rs.124.45 /- Lakhs.
- The Company has adjusted Rs. 5450.69/- Lakhs amortised discount cost and issue expenses on the issue of the Foreign Currency Convertible Bond against the balance laying in the Security Premium Account.
- Pursuant to receipt of Conversion notice from holder of the FCCBs, the company had allotted 7,13,96,581 Equity shares at Rs.2.34 /- (Issue price) on 01/04/2024 and 26,21,58,577 Equity Sahres at 2.39/- (Issue price) on 17/06/2024 in lieu of conversion of 20 and 75 FCCBs Bonds accordingly out of total 974 FCCBs.

For Evexia lifecare Limited


Rajesh Chakkar
Managing Director
DIN: 01631093

Date: 09th August, 2024
Place: Vadodara

